Dr. Shelly is the Director of Global Business Development and Strategic Partnerships, Essential Medicines for PATH. In this role, Dr. Shelly leads initiatives to seek out new and novel technologies for developing world diseases (vaccines, drugs, and devices) and will assist PATH in generating new/novel funding mechanisms. Prior to joining PATH, Dr. Shelly was Director of Business Development, R&D Externalization, and Clinical Development at Albumedix, a developer of novel recombinant albumin enabled therapeutics and immunotherapies. At Albumedix, Dr. Shelly drove significant licensing deals, was a key member of the R&D Externalization team and was the commercial lead on the Clinical Development team responsible for Albumedix’s clinical portfolio. Prior to Albumedix, he spent 8 years in the vaccine and gene therapy business where he focused on clinical development, regulation and manufacturing of Biopharmaceuticals (protein therapeutics, vaccines, gene therapies and VLPs) and prior to that, 2 years in clinical research and development. He is the author of several peer reviewed articles and book chapters. He is also an adjunct professor at the University of Cincinnati and recently won the Distinguished Adjunct Professor of the Year (2019).
Dr. Shelly teaches Drug and Biologics Discovery and Biotechnology Business Management courses in the UC College of Pharmacy’s Master of clinical Drug Development program. Dr. Shelly has a BA in biology from Lehigh University, an MA in Biology from the College of William and Mary, and a PhD (Molecular Physiology) at the Florida State University. He was a postdoctoral fellow in the U. of Cincinnati Department of Molecular and Cellular Physiology from 1997 to 2001 where he won the prestigious APS Fellowship in Physiological Genomics (one of two awards given annually) and a NRSA from the NIH. He obtained his MBA in Innovation Management from the U. of Cincinnati Lindner School of Management in 2002.